Key points are not available for this paper at this time.
BACKGROUND: This study aimed to evaluate the prognostic value of the newly revised International Association for the Study of Lung Cancer (IASLC) grading system (2020) on the 5-year overall survival (OS) and recurrence-free survival (RFS) in patients with lung adenocarcinoma (LADC). METHODS: Clinical studies that investigated the prognostic value of revised IASLC staging system in patients with LADC were retrieved from the PubMed, Web of Science, ScienceDirect, and Cochrane Library databases. This study was conducted in accordance to the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and checklists. RESULTS: Based on inclusion and exclusion criteria, we included 12 studies for analysis. The grade of LADC was assessed by revised IASLC system, which included three grades. Compared to Grade 3 LADC, grade 1 (total 95% CI: 1.38 1.19, 1.60) and grade 2 (total 95% CI: 1.29 1.15, 1.44) LADC had higher 5-year OS rates. Similarly, Grade 1 (total 95% CI: 1.76 1.42, 2.18) and Grade 2 (total 95% CI: 1.51 1.28, 1.77) had higher 5-year RFS rates Grade 3 LADC. However, 5-year OS and RFS had no significant difference between Grade 1 and Grade 2 patients. CONCLUSION: This systematic review and meta-analysis provides evidence that the newly revised IASLC grading system is significantly associated with the prognosis of patients with LADC, where Grade 3 indicated unfavorable prognosis.
Ruan et al. (Thu,) studied this question.